|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
Influenza-like symptoms |
|
upper respiratory tract infection |
|
Lower respiratory tract infection |
|
tooth or gingival disorder |
|
infectious diarrhea |
|
otitis |
|
urinary tract infection |
|
Abdominal pain |
|
gastrointestinal symptoms , including |
|
fatty/oily stool |
|
fecal incontinence |
|
fecal urgency |
|
flatus with discharge |
|
increased defecation |
|
oily evacuation |
|
oily spotting |
|
headache |
|
Anxiety |
|
back pain |
|
menstrual irregularities |
|
rectal pain or discomfort |
|
Arthritis |
|
dizziness |
|
dryness of skin |
|
fatigue |
|
insomnia |
|
myalgia |
|
nausea |
|
skin rash |
|
vomiting |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Anorexia nervosa |
|
Bulimia |
|
>> History of hyperoxaluria or calcium oxalate nephrolithiasis |
|
|
ADULT DOSE:
|
|
Obesity management-
Oral, 120 mg three times a day, with each fat-containing meal .
The dose should be taken during fat-containing meals or up to 1 hour after the meal .
Note: Doses in excess of 360 mg a day have not been shown to provide additional benefit . |
|
MAXIMUM ADULT DOSE:
|
|
360 mg a day .
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|